An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
13 05 2020
Historique:
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 21 10 2020
Statut: epublish

Résumé

For toxicity testing of airborne particles, air-liquid interface (ALI) exposure systems have been developed for in vitro tests in order to mimic realistic exposure conditions. This puts specific demands on the cell culture models. Many cell types are negatively affected by exposure to air (e.g., drying out) and only remain viable for a few days. This limits the exposure conditions that can be used in these models: usually relatively high concentrations are applied as a cloud (i.e., droplets containing particles, which settle down rapidly) within a short period of time. Such experimental conditions do not reflect realistic long-term exposure to low concentrations of particles. To overcome these limitations the use of a human bronchial epithelial cell line, Calu-3 was investigated. These cells can be cultured at ALI conditions for several weeks while retaining a healthy morphology and a stable monolayer with tight junctions. In addition, this bronchial model is suitable for testing the effects of repeated exposures to low, realistic concentrations of airborne particles using an ALI exposure system. This system uses a continuous airflow in contrast to other ALI exposure systems that use a single nebulization producing a cloud. Therefore, the continuous flow system is suitable for repeated and prolonged exposure to airborne particles while continuously monitoring the particle characteristics, exposure concentration, and delivered dose. Taken together, this bronchial model, in combination with the continuous flow exposure system, is able to mimic realistic, repeated inhalation exposure conditions that can be used for toxicity testing.

Identifiants

pubmed: 32478724
doi: 10.3791/61210
doi:

Substances chimiques

Particulate Matter 0
L-Lactate Dehydrogenase EC 1.1.1.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Hedwig M Braakhuis (HM)

National Institute for Public Health and the Environment (RIVM); hedwig.braakhuis@rivm.nl.

Ruiwen He (R)

National Institute for Public Health and the Environment (RIVM); Institute for Risk Assessment Sciences (IRAS).

Rob J Vandebriel (RJ)

National Institute for Public Health and the Environment (RIVM).

Eric R Gremmer (ER)

National Institute for Public Health and the Environment (RIVM).

Edwin Zwart (E)

National Institute for Public Health and the Environment (RIVM).

Jolanda P Vermeulen (JP)

National Institute for Public Health and the Environment (RIVM).

Paul Fokkens (P)

National Institute for Public Health and the Environment (RIVM).

John Boere (J)

National Institute for Public Health and the Environment (RIVM).

Ilse Gosens (I)

National Institute for Public Health and the Environment (RIVM).

Flemming R Cassee (FR)

National Institute for Public Health and the Environment (RIVM); Institute for Risk Assessment Sciences (IRAS).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH